ArticleEndocrine2021
Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Durable biochemical response and safety with oral octreotide capsules in acromegaly.European journal of endocrinology · 2022Trial
- Delayed diagnosis of acromegaly when lower facial features were obscured by masks during the COVID-19 pandemic.JCEM case reports · 2026Article
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.Journal of comparative effectiveness research · 2025Article
- Acromegaly and COVID-19, lessons, and new opportunities.Pituitary · 2024Article
- Pituitary surgery and COVID.Pituitary · 2024Review
- Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.Pituitary · 2023Article
- Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing's disease: a monocentric experience in Southern Italy.Journal of endocrinological investigation · 2023Article
- Pituitary and SARS CoV-2: An unremitting conundrum.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly.Medicina (Kaunas, Lithuania) · 2022Article
- Impact of the COVID-19 pandemic in the treatment of patients with acromegaly in a tertiary center: a wake-up call on the importance of telemedicine.Archives of endocrinology and metabolism · 2022Article
- [Pituitary and COVID-19: review].Problemy endokrinologii · 2022Review
- The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.Health science reports · 2021Review
- Pituitary adenoma…nomen omen?Endocrine · 2021Article
- One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology.European journal of endocrinology · 2021Article
- COVID-19 and the Endocrine System: A Comprehensive Review on the Theme.Journal of clinical medicine · 2021Review
- COVID-19 and the pituitary.Pituitary · 2021Review
- COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology.Endocrine · 2021Article
- Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting.Frontiers in endocrinology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With most global healthcare resources focused on COVID-19, altered resource allocation is disrupting the continuum of care for chronic endocrine conditions, including acromegaly. In order to assess the effects of COVID-19 on care of patients with acromegaly, we conducted an international online survey of endocrinologists. The questionnaire was drafted by a Steering Committee of acromegaly experts and covered both respondent demographics, contact and communication with patients, and patient care. Respondent awareness was generated through social media campaigns and the survey completed online using Google forms. The majority of endocrinologists who responded (N = 84) were based in Europe (67.9%) and were female (58.3%). Slightly more than half of respondents worked in a specialized pituitary center (52.4%) and a large minority cared for more than 50 acromegaly patients (47.6%). Most respondents (85.7%) indicated surgery was their first-line treatment, with only 14.3% indicating medical therapy as a first-choice treatment option. One-third (33.3%) of respondents reported having delayed a planned surgery due to a lack of COVID-19 testing provision and 54.8% due to a lack of surgical provision; 19.1% indicated that a lack of personal protective equipment had reduced their ability to treat patients with acromegaly. Just 21.4% of respondents reported no negative effects from the pandemic on diagnostic practice patterns, and just 19.1% reported no negative effect on patient follow-up practices. Many respondents (55.9%) indicated that remote methods had improved their ability to communicate with their patients and 69.0% indicated that they would continue to use methods of consultation necessitated by the COVID-19 pandemic. Our data suggest the COVID-19 pandemic is substantially affecting the care of acromegaly. However, these results also suggest that endocrinologists are embracing aspects of the 'new normal' to create a novel continuum of care better suited to the presumed post-COVID-19 environment. The goal of these changes must be both to improve care while shielding patients from more severe involvement in concomitant acute illnesses such COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.